Iteos Therapeutics Inc (ITOS) | |||
---|---|---|---|
13.64 0.47 (3.57%) | 03-28 16:00 | ||
Open: | 13.35 | Pre. Close: | 13.17 |
High: | 13.7 | Low: | 12.83 |
Volume: | 343,107 | Market Cap: | 489(M) |
Stock Technical Analysis | |
---|---|
Overall: | |
Target: | Six months: 16.00 One year: 18.69 |
Support: | Support1: 11.33 Support2: 9.87 |
Resistance: | Resistance1: 13.70 Resistance2: 16.00 |
Pivot: | 11.60 |
Moving Averages: | MA(5): 12.34 MA(20): 11.54 MA(100): 10.62 MA(250): 11.97 |
MACD: | MACD(12,26): 0.48 Signal(12,26,9): 0.25 |
%K %D: | %K(14,3): 94.67 %D(3): 78.47 |
RSI: | RSI(14): 70.08 |
52-Week: | High: 18.24 Low: 8.2 Change(%): 3.4 |
Average Vol(K): | 3-Month: 268 10-Days: 283 |
Prices Prediction (Update @5:00pm) | ||
---|---|---|
If tomorrow: | Open lower | Open higher |
High: | 13.701 - 13.749 | 13.749 - 13.793 |
Low: | 12.698 - 12.757 | 12.757 - 12.811 |
Close: | 13.542 - 13.628 | 13.628 - 13.707 |
Price, MAs and Bollinger Bands |
---|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ITOS ] has closed above the upper band by 6.2%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 124.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue. |
Company profile |
---|
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts. |
Stock chart |
---|
Financial Analysis | |
---|---|
Price to Book Value: | Neutral |
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. | |
Price to Earnings: | Underperform |
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). | |
Discounted cash flow: | Neutral |
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. | |
Return on Assets: | Neutral |
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. | |
Return on Equity: | Underperform |
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. | |
Debt to Equity: | Underperform |
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Stock Basics & Statistics | |
---|---|
Exchange: NASDAQ Global Market | |
Sector: Healthcare | |
Industry: Biotechnology | |
Shares Out. (M) | |
Shares Float (M) | 35.84 |
% Held by Insiders | 24790000.00 |
% Held by Institutions | 0.54 |
Shares Short (K) | 1730 |
Shares Short Prior Month (K) |
Stock Financials | |
---|---|
EPS | -146680000.000 |
Book Value (p.s.) | |
Profit Margin | |
Operating Margin | |
Return on Assets (ttm) | 171.7 |
Return on Equity (ttm) | -13.0 |
Qtrly Rev. Growth | 12600000.0 |
Gross Profit (p.s.) | -86.957 |
Sales Per Share | -15.817 |
EBITDA (p.s.) | |
Qtrly Earnings Growth | -3.15 |
Operating Cash Flow (M) | |
Levered Free Cash Flow (M) | -103.76 |
Stock Valuation | |
---|---|
PE Ratio | |
PEG Ratio | |
Price to Book value | |
Price to Sales | -0.86 |
Price to Cash Flow | 0.98 |
Stock Dividends | |
---|---|
Dividend | |
Dividend Yield | |
Dividend Growth | 1800000.000 |